Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia
- First Posted Date
- 2014-01-23
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT02042911
- Locations
- 🇯🇵
Research Site, Kagoshima, Japan
Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT02014051
- Locations
- 🇯🇵
Research site, Kyoto, Japan
Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT02002936
- Locations
- 🇯🇵
Research Site, Kyoto, Japan
Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT02000154
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
🇯🇵Research site, Isesaki, Kanagawa, Japan
Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT01849848
Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT01718691
- Locations
- 🇯🇵
Research site, Tokyo, Japan
Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2014-11-19
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 189
- Registration Number
- NCT01700140
- Locations
- 🇯🇵
Research Site, Koshigaya, Saitama, Japan
🇯🇵Research, Kyoto, Japan
🇯🇵Reseach site, Tokyo, Japan
Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT01700335
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2013-03-18
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT01179490
- Locations
- 🇯🇵
Research site, Fukuoka, Japan
Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2013-07-04
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 63
- Registration Number
- NCT01118845
© Copyright 2024. All Rights Reserved by MedPath